Last reviewed 2026-04-20 · How we verify

Enbrel

At a glance

Approved indications

• Ankylosing spondylitis
• Juvenile idiopathic arthritis
• Nonradiographic axial spondyloarthritis
• Plaque psoriasis
• Psoriasis with arthropathy
• Rheumatoid arthritis

Common side effects

• Infections
• Injection site reactions
• Upper respiratory tract infection
• Sinusitis
• Influenza

Serious adverse events

• Serious infections
• Tuberculosis
• Pneumonia
• Sepsis
• Neurologic events
• Congestive heart failure (CHF)
• Hematologic events
• Cellulitis
• Septic arthritis
• Osteomyelitis

Key clinical trials

• Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
• A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis (PHASE2, PHASE3)
• Treatment Tapering in JIA With Inactive Disease (PHASE3)
• Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis (PHASE3)
• Psoriasis Longitudinal Assessment and Registry
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants (PHASE3)
• TNF-α Treatment of Blast-Induced Tinnitus (PHASE2)
• Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Enbrel CI brief — competitive landscape report
• Enbrel updates RSS · CI watch RSS
• LG Life Sciences portfolio CI